← Human Trials & Peer-Reviewed Studies
The Effect of Vitamin D3 Supplementation on the Risk of Falls in a General Population-The Finnish Vitamin D Trial.
Plain-language guide to PMID 41531181 (2026): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 2495 participants.
Key Facts
- PMID
- 41531181
- Journal
- Journal of the American Geriatrics Society
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Rikkonen T et al. (10 authors)
- DOI
- 10.1111/jgs.70295
- Registered trial
- NCT01463813
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
The impact of vitamin D on fall incidence remains controversial.
Who Took Part
The study group was 2495 participants.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
A random subgroup of 551 participants underwent more detailed examinations.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
Falls and fall-related injuries were collected with questionnaires at months 0, 12, 24, 36, and 60.
General linear mixed models and generalized linear models were used for analyses.
What Was Measured
PubMed files the paper under topics including Accidental Falls, Finland, Cholecalciferol, Dietary Supplements, Vitamins, Incidence and Risk Factors.
The authors tagged it with the keywords randomized trial, supplementation and vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2495 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Journal of the American Geriatrics Society), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.